Literature DB >> 12351643

Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion.

Nirmal Gosavi1, He-Jin Lee, Jun Sung Lee, Smita Patel, Seung-Jae Lee.   

Abstract

Amyloid-like fibrillar aggregates of intracellular proteins are common pathological features of human neurodegenerative diseases. However, the nature of pathogenic aggregates and the biological consequences of their formation remain elusive. Here, we describe (i) a model cellular system in which prefibrillar alpha-synuclein aggregates and fibrillar inclusions are naturally formed in the cytoplasm with distinctive kinetics and (ii) a tight correlation between the presence of prefibrillar aggregates and the Golgi fragmentation. Consistent with the structural abnormality of Golgi apparatus, trafficking and maturation of dopamine transporter through the biosynthetic pathway were impaired in the presence of alpha-synuclein aggregates. Reduction in cell viability was also observed in the prefibrillar aggregate-forming condition and before the inclusion formation. The fibrillar inclusions, on the other hand, showed no correlation with Golgi fragmentation and were preceded by these events. Furthermore, at the early stage of inclusion formation, active lysosomes and mitochondria were enriched in the juxtanuclear area and co-aggregate into a compact inclusion body, suggesting that the fibrillar inclusions might be the consequence of an attempt of the cell to remove abnormal protein aggregates and damaged organelles. These results support the hypothesis that prefibrillar alpha-synuclein aggregates are the pathogenic species and suggest that Golgi fragmentation and subsequent trafficking impairment are the specific consequence of alpha-synuclein aggregation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351643     DOI: 10.1074/jbc.M208194200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  120 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

Review 3.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  Fragmentation of the Golgi apparatus induced by the overexpression of wild-type and mutant human tau forms in neurons.

Authors:  Dalinda Liazoghli; Sebastien Perreault; Kristina D Micheva; Mylène Desjardins; Nicole Leclerc
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

5.  Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.

Authors:  Małgorzata Pokrzywa; Katarzyna Pawełek; Weronika Elżbieta Kucia; Szymon Sarbak; Erik Chorell; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

6.  Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.

Authors:  Cheryl Dixon; Neal Mathias; Richard M Zweig; Donnie A Davis; David S Gross
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

Review 7.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

8.  Membrane remodeling by α-synuclein and effects on amyloid formation.

Authors:  Zhiping Jiang; Michel de Messieres; Jennifer C Lee
Journal:  J Am Chem Soc       Date:  2013-10-17       Impact factor: 15.419

9.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

10.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.